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Abstract 
Background: Traditional quantitative structure-activity relationship models usually neglect the molecular alterations 
happening in the exposed systems (the mechanism of action, MOA), that mediate between structural properties of 
compounds and phenotypic effects of an exposure.
Results: Here, we propose a computational strategy that integrates molecular descriptors and MOA information 
to better explain the mechanisms underlying biological endpoints of interest. By applying our methodology, we 
obtained a statistically robust and validated model to predict the binding affinity to human serum albumin. Our 
model is also able to provide new venues for the interpretation of the chemical-biological interactions.
Conclusion: Our observations suggest that integrated quantitative models of structural and MOA-activity relation-
ships are promising complementary tools in the arsenal of strategies aiming at developing new safe- and useful-by-
design compounds.
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Introduction
Quantitative structure-activity relationship (QSAR) 
models are increasingly applied in various fields, such 
as toxicity assessment and drug design [1]. QSAR mod-
els developed and validated in line with the Organization 
for Economic Co-Operation and Development (OECD) 
criteria [2] are recognized in silico tools for provid-
ing reliable activity data, bypassing long and laborious 
experimental assays. On the basis that structurally simi-
lar molecules have similar biological activities, classical 
QSAR models attempt to predict activity as a function of 
structural properties numerically defined as molecular 
descriptors (MDs) [1, 3]. MDs provide extensive chemi-
cal information, such as presence and count of different 
sub-structures, functional groups, connectivity between 
atoms, topological and geometrical characteristics, 
which are relevant for predictive studies. Furthermore, 
3D alignment-free molecular descriptors, based on two, 
three and four linear algebraic forms have been intro-
duced to codify novel and orthogonal chemical informa-
tion [4, 5].
Traditional QSAR models usually neglect the primary 
biological fingerprint of the exposure, consisting of the 
ensemble of molecular alterations happening at various 
cellular compartments of the exposed biological system, 
hereafter denoted as the mechanism of action (MOA). 
However, the relationship between structural properties 
and phenotypic effects of an exposure is indirectly medi-
ated by its MOA. Systematically integrating MOA infor-
mation, such as gene expression or external bioassay data, 
into QSAR modelling would expand our understanding 
of the chemical-biological interactions, hence paving the 
way to the development of the next generations of safe- 
and useful-by-design compounds [6, 7].
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In the recent years, the implementation of omics tech-
nologies in toxicology studies has ignited the new field of 
toxicogenomics [8]. In this context, in depth molecular 
profiling opened new possibilities to outline the biosigna-
ture or MOA of exposures at an unprecedented granular-
ity. However, to date, this information has been seldom 
utilized in combination with structural properties of the 
compounds to predict their effects [9–11].
Indeed, Li et  al developed a methodology that jointly 
analyzes the chemical structural information and the 
gene expression profiles of cells treated by drugs. By 
means of a clustering methodology, they identified the 
most structurally similar sets of chemicals and the mini-
mum set of genes related to chemical structural features 
[9]. Low et  al. [10] used a machine learning methodol-
ogy based on multiple nonlinear classifiers that inte-
grates chemical descriptors and toxicogenomic data to 
classify drug molecules based on their hepatotoxicity 
(toxic/or non-toxic) effect in rats. Perualila-Tan et al. [11] 
proposed a statistical methodology that combines tran-
scriptomic data and chemical information to predict a 
biological response by means of gene expression and infer 
if the response is caused by the presence or absence of a 
particular chemical sub-structure. These approaches are 
limited to binary classification problems (toxic/non toxic) 
and to the identification of correlations between MDs 
and MOA features. However, when modelling a continu-
ous response variable, integrative regression models are 
a preferred option. Between the wide range of linear and 
nonlinear regression models, Lasso based methods have 
the advantage to generate easy to interpret models, since 
they automatically perform feature selection and have 
less parameter to be estimated as compared to nonlinear 
models, such as random forests, support vector regres-
sors or neural networks.
Here, considering the OECD criteria [2], we propose a 
computational approach that combines MDs and MOA 
information to develop integrated quantitative structure 
and mechanism of action-activity relationship (QSMARt) 
models with the potential to better explain the role of 
specific structural properties in a bio-mechanistic way. 
To the best of our knowledge, the present study is the 
first report on an integrated QSMARt model to predict 
the binding affinity to HSA.
Materials and methods
Dataset preparation 
Curated experimental binding affinity data of drug and 
drug-like molecules to HSA ( logKHSA ; the binding con-
stant obtained from the retention time on an immobi-
lized HSA column using affinity chromatography) were 
obtained from [12]. All structures (as 3D SDF files) 
were retrieved from PubChem [13] and processed by 
the software DRAGON v. 7.0 [14] for the calculation 
of 5,325 MDs. An unsupervised feature reduction was 
applied to filter the constant ( > 80% ) and highly intercor-
related descriptors (pairwise correlation among all pairs 
of descriptors > 95% ) prior to training/test set splitting, 
and variable selection [15]. Thus, a data matrix compris-
ing 1,198 MDs was generated (hereafter denoted as A). 
Transcriptomic data for drug treatments were retrieved 
from the Connectivity Map (CMap) build v2.0 repository 
[16]. Three human cell lines were available in the CMap 
project: prostate cancer (PC3), breast cancer (MCF7), 
and leukemia (HL60), respectively. The transcriptomic 
datasets were analyzed independently for each cell line. 
Raw data was imported into R v. 3.4 by using the jus-
tRMA function from the Bioconductor utilities [17] to 
annotate probes to Ensembl genes (by using the hth-
gu133ahsensgcdf (v. 22.0.0) annotation file from the 
brainarray website http://brain array .mbni.med.umich 
.edu/), and to quantile normalize the resulting expres-
sion matrix. Next, the experimental batch effect due to 
technical variables was estimated and removed using the 
ComBat algorithm implemented in the sva package [18]. 
Linear models followed by eBayes pairwise comparisons 
[19] were performed to compute the log fold-change of 
each gene in each drug-control pairs. Of the 88 chemi-
cals in the curated dataset [12], 59 were identified with 
reported gene expression data for at least two cell lines 
of the CMap dataset (MCF7 and PC3). The list of drugs 
used in this analysis is available in Additional file  1. 
Consequently, two data matrices of log-fold changes 
for 11,868 genes in MCF7 (hereafter denoted as B) and 
PC3 cell lines (hereafter denoted as C) were generated, 
respectively. Finally, MDs (A) and gene expression pro-
files (B and C) were collated to create a single dataset 
(hereafter denoted as X) of 59 drugs and 24,934 features 
(1198 MDs and 11,868 genes for each cell line) for mod-
eling the logKHSA.
Modeling and validation
QSMARt modeling was performed based on the lasso 
method [20] and power transformation of the MDs ( α ) 
and genes ( γ ), respectively. 20% of the dataset X was 
kept as the test set and not used in the model selection 
phase. The remaining 80% of the data (training set) was 
further split 100 times in random training (90%) and 
validation (10%) sets by using a random split validation 
algorithm (RSVA). The splitting was performed based 
on the y-response variable, which was divided into three 
bins, from which the compounds are randomly assigned 
to train or test sets. Detailed methodology available as 
in Additional file 2. R scripts are available as Additional 
file 3. Next, the lasso method is used to fit a linear model 
to the training set for 100 different values of the lasso 
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penalty estimated from the training matrix [21]. The lasso 
penalization value leading to the smallest mean squared 
error (MSE,  = 0.166 ), was considered (Additional file 4: 
Fig. S1). Only the features (MDs and/or genes) with non-
zero coefficients were selected to derive the final model. 
Once the optimal features and parameters were iden-
tified, the entire training set was used to build the final 
model and the test set was only then used for external 
validation.
The following model was considered to predict the 
logKHSA:
where, X(α, γ ) is the matrix obtained by binding the 
matrices of A(α) , B(γ ) , and C(γ ) , A(α) = (|aij|α) , 
B(γ ) = (|bij|
γ ) , C(γ ) = (|cij|γ ) (for α > 0 and γ > 0 ), β 
is the vector of coefficients, and ǫ is the stochastic error, 
respectively.
The same power transformation ( γ ) was used both for 
the MCF7 (B) and PC3 cell line (C). Considering α and 
γ fixed, and β the only structural/genomic parameter to 
be estimated, is conceptually equivalent to replacing the 
original sample measurements X with X(α, γ ) . For fixed 
α and γ , the following lasso-type estimator is considered:
where || · ||2 is the euclidean norm, || · ||1 is the l1 norm 
and  is the lasso penalty.
The parameters (α,β , γ ) were tuned to minimize 
the MSE on the training set. The RSVA was per-
formed for a grid of nine distinct α and γ values 
( α, γ = 0.1, 0.25, 0.50, 0.75, 1, 1.25, 1.50, 1.75, 2 ) for all 
81 possible pairs of (αi, γi) with i = 1, . . . , 81 . For each 
of the 81 combinations, the relevant set of features 
ft = β(αt , γt) (at t = 1, 2, . . . , 81) associated with non-
zero coefficients was identified, validated the 60th per-
centile values of the distributions of the internal metrics 
computed on the multiple splits were considered), and 
used to train models on the whole training set. Next, the 
generated models were used to predict the logKHSA on 
the test set. Following these steps, a population of candi-
date models was generated. Goodness of fit, robustness, 
and predictive performance of the candidate models were 
evaluated based on up-to-date internal and external vali-
dation parameters and criteria (Additional file 1) [22–28].
Comparison with single view models
In order to validate the QSMARt model, the same pro-
cedure was applied to the MDs and MOA features sep-
arately. The RSVA procedure was performed on nine 
α = 0.1, 0.25, 0.50, 0.75, 1, 1.25, 1.50, 1.75, 2 values for the 
MDs and nine γ = 0.1, 0.25, 0.50, 0.75, 1, 1.25, 1.50, 1.75, 2 
values for the MOA features. Furthermore, these two 
(1)y = X(α, γ )β + ǫ
(2)βˆ = argmin||y− X(α, γ )β||22 + ||β||1
parameters, together with the  penalty, value were opti-
mized independently for the MDs and MOA to identify 
the optimal setup that minimizes the MSE on the train-
ing set. These analyses led to 9 models for the MDs and 
9 models for the MOA features. For each model, the rele-
vant set of features, associated with non-zero coefficients, 
was identified and validated with the same approach 
described before. Goodness of fit, robustness, and pre-
dictive performance of the candidate models were evalu-
ated based on up-to-date internal and external validation 
parameters and criteria (Additional file  1) [22–28]. In 
particular, distributions of the internal validation metrics 
computed with the RSVA procedure with 100 random 
splits were compared to identify which model overall give 
the better predictive performances.
Applicability domain
Based on the idea of consensus decision[29], differ-
ent approaches were used to compute the applicability 
domain (AD) of the identified models. In particular, AD 
was computed by means of the leverage method [30], 
the standardization approach [31], the euclidean [32] 
and city block distance methods [33], and the k-nearest 
neighbours method [34].
In the leverage method, the response outliers were 
determined as those with the predicted activity value 
> ±3.0 standardized residuals. The leverage value (h) 
measures the distance from the centroid of the modeled 
space. A warning leverage (critical hat value, h*) [30] was 
used to identify structural/MOA influential compounds 
( h > h∗ denoting high-leverage chemicals). In a Williams 
plot [30], the leverage values were mapped against the 
standardized residuals to define the structural/MOA and 
the response spaces visually. Finally, the AD was reported 
as the percentile coverage for the training ( ADTrain ) and 
test ( ADTest ) set, respectively. Moreover, the Insubria 
graph [15] of leverage values against calculated/predicted 
activity values was used to visualize the interpolated 
( h < h∗ denoting chemicals inside the structural/MOA 
AD of the training set) and extrapolated ( h > h∗ char-
acterizing chemicals outside the structural/MOA AD) 
predictions for all the datasets considered in this study. 
In this case, the response AD was the prediction range of 
the model.
The standarization approach [31] is based on the 
assumption that in case of normal distribution, 99.7% of 
the population will remain within the range mean ±3.0 
standard deviation (SD). Thus, all molecular descriptors 
are first standardized. Afterwards, any compound out-
side this zone is dissimilar to the rest and majority of the 
compounds. Thus, if the standardized value for descrip-
tor i of compound k is more than 3, then the compound 
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should be an X-outlier (if in the training set) or outside 
AD (if in the test set) based on descriptor i.
In the distance based methods [32–34], the distance 
between the chemical and the center of the training data 
set is computed. The threshold, for both Euclidean and 
City block distances, is the largest distance between the 
training set data points and the center of the training data 
set. Furthermore, the distance between the test samples 
and the center of the dataset is computed. The test points 
with a distance greater than the computed threshold are 
considered outliers. The AD was reported as the percen-
tile coverage of the test set ( ADTest).
In the k-nearest neighbours method [34], the distance 
between every train compound and its k-nearest neigh-
bours in the training set is computed. A threshold is cal-
culated as the largest of these distances. Subsequently, 
the distance between every test compounds and its 
k-nearest neighbours in the training set is computed. If 
the calculated distance values of test set compounds is 
within the defined threshold, then the prediction of these 
compounds are considered to be reliable. In this method 
the k value was set to 3. The AD was reported as the per-
centile coverage of the test set ( ADTest).
The final consensus value on the training compounds is 
computed as a mean of the leverage and standardization 
methods, while the consensus on the test set is computed 
as the mean of all the different approaches.
Selection of the final model
Among the generated candidate models, the one with 
the best compromise between statistical robustness, 
predictive performance, widest AD, and smallest dimen-
sion was selected as the final model. To this end, all 81 
alternative specifications were filtered based on multi-
ple up-to-date statistical acceptance criteria (highlighted 
in Additional file  1). Only the models both satisfying 
the internal and external validation requirements, and 
providing 100% ADTest coverage, with the consensus 
method, were considered eligible. Moreover, the trans-
formation parameters ( α∗,γ ∗ ) achieving the best predic-
tive performance were selected as the set of indices of 
eligible solutions by solving (α∗γ ∗) = argmint(E(αt , γt); 
t ∈ I) with I ⊆ {1, . . . , 81} . Finally, the model satisfying 
all eligibility criteria, consisting of the smallest number 
of structural/MOA features, and with the widest ADTrain 
coverage was selected as the ultimate model.
Application of the final model
The optimal model was applied to a set of external com-
pounds for which the logKHSA is unavailable. To this pur-
pose, an independent set of 799 drugs from the CMap 
dataset [16] with gene expression data available on both 
MCF7 and PC3 cell lines was considered. SDF files for 
these compounds were retrieved from PubChem [13] 
and fed into DRAGON v. 7.0 [14] to generate molecu-
lar descriptors. Gene expression data was preprocessed 
similarly to the dataset of 59 compounds, as described 
above. The list of drugs in the external dataset is avail-
able in Additional file 1. The TSNE projection technique 
[35] was used to visualize the distribution of the albumin 
and the external datasets based on the six MDs/MOA 
features of the QSMARt model as well as the three MOA 
features and three MDs.
Results and discussion
QSMARt predictive model for the binding affinity to HSA
Here, we built an integrated model (QSMARt) comprising 
molecular descriptors and MOA features to predict binding 
affinity to human serum albumin. To this end, we derived 
81 candidate models by applying a Lasso penalty parameter 
optimisation. The 81 models and their evaluation metrics 
are reported in Additional file  1. The full lists of selected 
MDs and genes, along with their occurrence frequencies, 
are available in Additional file 1. Upon rigorous evaluation 
based on the OECD validation principles [2], we selected a 
final model of six structural/MOA features: three molecu-
lar descriptors and three gene expression patterns (Eq. 3).
A good concordance between the predicted and experi-
mental data is shown in Fig. 1. Our model fulfils the cri-
teria regarding the goodness of fit and the internal and 
(3)
LogKHSA = −0.372+ 0.012|Mor23i|
1.25
− 0.042|N − 072|1.25 + 0.139|ALOGP|1.25
− 2.980|MCF7_ENSG00000112115|1.75
− 0.075|PC3_ENSG00000197646|1.75
− 0.216|PC3_ENSG00000276644|1.75
Fig. 1 Predicted logKHSA versus experimental logKHSA values of 
training set (black) and test set (red) chemicals
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external validation requirements, as shown in Additional 
file  1. Moreover, the final hybrid model statistics passed 
all the recommended thresholds except the CCC metric 
(Additional file 1). Indeed, the QL10−Out , R2tr , R2te , Q2F1 , Q
2
F2
 , 
Q2F3 are greater than 0.6, but, the CCCTe value is smaller 
than 0.85. Next, we defined the AD of our model based on 
the consensus strategy. Noteworthily, all chemicals of the 
test set are inside the AD spaces (Additional file  1), sug-
gesting that all the predictions were reliably interpolated. 
For visualization purposes we show the AD computed by 
means of the the leverage approach [30] in Fig. 2.
Impact of the integration approach and comparison 
to sub‑models
Next, in order to evaluate the impact of the integration 
strategy, we compared our QSMARt integrated final 
model with the two obtained by applying our approach 
to the MDs and genes separately. We ran the SVA meth-
odology for the same nine α and γ values and we obtained 
9 models for the MDs, while only two models were 
obtained by using the genes alone, since no fitting was 
obtained for 7 γ values. The best models for the MDs and 
genes respectively are the following:
(4)
LogKHSA = −0.335+ 0.077|Mor23i|
0.11 − 0.012|R8s.|0.11
+ 0.007|C .040|0.11 − 0.061|N − 072|0.11
+ 0.062|ALOGP|0.11 − 0.003|CATS3D06AP.|
0.11
+ 0.0006|piPC08|0.11 − 0.010|GATS2i|0.11
+ 0.001|SpMax1Bh.v.|
0.11
As evidenced in Additional file 1, the QSMARt model is 
characterized by overall better values of all the relevant 
diagnostic statistics. This analysis, hence, highlighted an 
overall better statistical performance of the integrated 
QSMARt model (Eq. 3) over the two competitor models 
(Eq. 4 and Eq. 5). In particular, the QSMARt model con-
sists of less features, since it uses only 3 MDs and 3 genes, 
while the other two models use 9 MDs and 9 genes, 
respectively. Furthermore, the model coming from the 
genes does not show any predictive capability on the test 
set ( R2test = 0.10 ) although its R2train = 0.61 . On the other 
hand the model obtained by using only MDs has good 
predictive capabilities, even thought they are smaller 
than the one obtained by the QSMARt model. Further-
more, when comparing the distributions of the Q2 , Q2F1
,Q2F2 , Q2F3 and CCC metrics that are computed with the 
RSVA method, the performances of the QSMARt model 
are better than those of the other two models (Additional 
file 5: Fig. S2).
Mechanistic interpretation of the features included 
in the QSMARt model
Mechanistic interpretation of the molecular descrip-
tors included in a model is an OECD principle of QSAR 
validation [2]. The hybrid model was built with the fol-
lowing MDs: Mor23i, N-072, and ALOGP. Mor23i is a 
measure of the pair-wise interatomic distance and ioniza-
tion potential [36]. Ionization potential is the amount of 
energy required to extract one electron from a chemical 
system, i.e., a measure of the capability of a molecule to 
give the corresponding cation. Mor23i and logKHSA are 
positively correlated (Eq. 3), implying that the higher the 
ionization potential, the higher the HSA binding affin-
ity. This further suggests that electron-pair acceptors 
(Lewis-acids) have higher binding affinity to HSA. Given 
the positive coefficient of Mor23i in our model equa-
tion, compounds with more acidic properties have higher 
binding affinity to HSA. On the other hand, due to the 
mathematical background, the distance between two 
influential atoms may majorly define the descriptor [36]. 
(5)
LogKHSA = 0.042+ 3.84|MCF7_ENSG00000185950|
0.16
− 11.163|MCF7_ENSG00000112115|0.16
− 0.758|MCF7_ENSG00000135100|0.16
+ 0.193|PC3_ENSG00000128228|0.16
+ 0.0007|PC3_ENSG00000168209|0.16
+ 0.040|PC3_ENSG00000110619|0.16
− 0.755|PC3_ENSG00000064687|0.16
− 1.310|PC3_ENSG00000168875|0.16
− 9.301|PC3_ENSG00000276644|0.16
Fig. 2 Standardized residuals versus leverage values of training 
set (black) and test set (red) chemicals (Williams plot). Dashed lines 
indicate 3.0σ interval. Vertical line set at the warning leverage (critical 
hat value, h∗ = 0.438)
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Therefore, a more detailed interpretation could be useful 
for molecular design purposes.
N-072 is a descriptor counting the nitrogen-centered 
fragments of RCO-N< or > N-X=X in a chemical struc-
ture, where R is any group bound through carbon, X is 
any electronegative atom, such as oxygen, nitrogen, sul-
fur, phosphorus, and halogens, - is single and = is dou-
ble bonds, respectively [3]. The negative coefficient in 
the final model indicates that chemicals with N-072 frag-
ments show less affinity to HSA binding. Similarly, N-072 
was reported elsewhere as affecting the relative fluores-
cence intensity ratio [37].
ALOGP is a measure of hydrophobicity as the loga-
rithm of n-octanol/water partition coefficient. Based on 
the Ghose-Crippen method [38], it is calculated as the 
summation of atomic contributions to overall molecu-
lar hydrophobicity. Clearly, having a positive coefficient 
in the model equation, ALOGP explains an increased 
affinity to HSA binding. It has been already reported in 
relation to binding affinity to HSA [12, 39]. Furthermore, 
earlier studies on the crystallographic structure of HSA 
and binding affinity evidenced that the binding sites of 
HSA are mainly composed of hydrophobic residues, fur-
ther revealing that hydrophobicity is a major property 
encoding the binding affinity, as reviewed in [40, 41].
Three genes are included in the final QSMARt model, 
namely Interleukin 17A (IL17A) from the MCF7, Pro-
grammed Cell Death 1 Ligand 2 (PD-L2), and Dachshund 
Family Transcription Factor 1 (DACH1) from the PC-3 
transcriptomic datasets, respectively. The expression 
of IL17A is documented in the MCF7 cell line, where 
it has been tested as target of chemotherapeutic strate-
gies aiming at altering autophagic ability of breast cancer 
cell lines [42]. Alteration of the expression of PD-L2, a 
ligand of PD-1, has been observed both in prostate can-
cer in response to anti-PD-1 therapy [43]. DACH1 is a 
transcription factor expressed in prostate cancer, where 
its low expression is associated with higher malignant 
potential [44]. Interestingly, all these three genes have 
known immunomodulatory properties, either as pro-
inflammatory (IL17A) or immunosuppressive (PD-L2 
and DACH1). Since their QSMARt model coefficients 
are negative, the impact of drugs to alter their expression 
is inversely proportional to HSA binding affinity. These 
results, for instance, suggest that the serum supplemen-
tation in the cell culture medium and the compound 
dosages should be mutually adjusted when testing drugs 
in vitro, such as in the CMap experiments.
Next, we considered the correlation between the three 
gene expression patterns and the three MDs included in 
the QSMARt model (Fig. 3). All the genes in the model 
were negatively correlated with Mor23i and ALOGP, 
and positively correlated with N-072, respectively. These 
results imply that potentially less acidic (lower values of 
Mor23i) and less lipophilic compounds (lower values of 
ALOGP) have a higher impact in altering the expression 
of these three genes.
Altogether, according to the QSMARt model, com-
pounds with higher values of ionization potential and 
hydrophobicity, and less nitrogen-centered residuals, as 
well as lower expression alteration of the immunomod-
ulatory genes IL17A, PD-L2 and DACH1, have higher 
binding affinity to HSA.
Fig. 3 Correlation graph of the six MDs/MOA features of the QSMARt 
model. Vertex color represent the sign of the associated beta value 
while edge colors show the sign of the correlation of the features 
across the X dataset
Fig. 4 Predicted logKHSA by Eq. 3 versus leverage values of training 
set (black), test set (red), and external set (green) chemicals (Insubria 
graph). Dashed lines indicate the model prediction range. Vertical line 
set at the warning leverage (critical hat value, h∗ = 0.438)
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Taken together, these results provide an extended 
mechanistic interpretation of the interactions of chemi-
cals and biological systems by providing direct asso-
ciations between specific structural and biological 
properties of the exposure.
Application of the QSMARt model
Finally, we tested the performance of our QSMARt 
model in predicting the logKHSA for an independent set of 
799 compounds extracted from the CMap dataset. With 
741 chemicals in the AD, our model provided a remark-
able prediction coverage of 93% (Fig. 4). It is noteworthy 
to emphasize that no external chemicals falling outside 
the structural/MOA feature domain were identified. 
However, 58 drugs appeared outside the model predic-
tion range and were further investigated. For this, we 
inspected the distribution of the different subsets of 
compounds in a projected space based on the six MDs/
MOA features of the QSMARt model (Fig. 5a) as well as 
the three MOA features (Fig. 5b) and three MDs (Fig. 5c) 
considered separately. This analysis evidenced that the 
external set chemicals falling outside the model pre-
diction range show less structural commonalities with 
the rest of the compounds (Fig. 5c) but are genomically 
confounded with the others (Fig.  5b). Thus, we further 
investigated the value of the MDs for the external dataset 
and, as we can see from Fig. 5d, drugs falling outside the 
prediction range of our model have higher value for the 
ALOGP MD.
a b
c d
Fig. 5 TSNE projection of the drugs in the albumin and external dataset. The projection was performed by using the set of genes and MDs (a), 
only the genes (b) and only the MDs (c) in the optimal hybrid model. The outliers are in the border area of the dataset for the molecular descriptors 
(c), while they are similar to the rest of the external set fort the gene log-fold change (b). Likewise, the outliers still appear on the border for the 
combined two sets of features (a). In panel (d) the values of the three MDs is plotted (y axis) for the drugs in the albumin and external dataset (x 
axis). The drugs are ordered based on their predicted logKHSA value. Drugs from the external set that falls in the model prediction range are marked 
in gray, while the ones that are outside the range are marked in blue. Drugs in the training set are marked in black while drugs in the test set are 
marked in red
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Biological relevance of the QSMARt model
In order to better understand the possible impact of the 
QSMARt model, we investigated its performance on 
drugs grouped by the ATC (Anatomical, Therapeutic, 
Chemical) code system as defined by the World Health 
Organization (WHO) [45]. The ATC codes classify the 
drugs into different groups in accordance with the organ 
or system on which they act and their chemical, pharma-
cological, and therapeutic properties. We performed our 
analyses by considering the anatomical subgroup (level 1) 
and the therapeutic subgroup (level 2) of the ATC codes. 
We investigated the relationship between the experimen-
tal vs. predicted logKHSA values, of the 59 drugs present 
in our dataset, and their grouping in ATC level 1 and 2 
(Additional file  6: Fig. S3). This analysis highlights that 
the two drugs cefuroxime and amoxicillin, belonging 
to the ATC class J (any-inflammatory), show the lowest 
range of experimental and predicted logKHSA. Likewise, 
a large group of ATC class C compounds (cardiovascu-
lar system) are in the mid range of the distribution, while 
four ATC class N (nervous system) are grouped in the 
highest range of the experimental/predicted logKHSA. 
Next, we inspected the larger set of 799 drugs used for 
the external validation, for which no experimental value 
of logKHSA was available. In this case, we looked at the 
distribution of the predicted logKHSA values in the level 
1 and level 2 ATC codes (Additional files 7: Fig. S4 and 
8: Fig. S5). Also, this analysis shows that the compounds 
belonging to the ATC class J (anti-inflammatory) have 
the lowest levels of predicted logKHSA. On the opposite, 
drugs of the ATC class A (digestive system), G (genitou-
rinary system) and N (nervous system) have the highest 
predicted logKHSA. These results confirm our observa-
tions on the 59 drugs present in our discovery set.
The genes selected in our model are involved in several 
signalling pathways, especially in cancer and immune 
signalling. Thus, we investigated their expression values 
between immunomodulatory and non immunomodu-
latory compounds. We identified the level 2 classes L03 
and L04 to be immunostimulant and immunosuppres-
sant, respectively. Unfortunatelly, none of the compounds 
available in the Connectivity map data set belong to the 
class L03, while four are annotated as L04. To perform the 
comparison, we selected the compound structurally least 
similar to each of the L04 drugs in the Connectivity Map 
dataset, and plotted the respective expression values for 
each of the three genes included in our final model (Addi-
tional file  9: Fig. S6). While MCF7_ENSG00000112115 
And PC3_ENSG00000197646 did not show any differ-
ence, the gene PC3_ENSG00000276644 showed a trend 
with higher expression in L04 drugs as compared to their 
least similar ones.
Conclusion
In this study, we proposed a computational strategy to 
define quantitative models of structural and mechanism 
of action-activity relationships (QSMARt). Moreover, we 
investigated the effectiveness of hybrid QSMARt model 
comprising both MDs and MOA information to better 
explain the biological mechanisms underlying endpoints 
of interest. We applied our methodology to predict 
human serum albumin (HSA) binding, obtaining a sta-
tistically robust and validated model that provides new 
venues for the interpretation of the chemical-biological 
interactions. QSMARt models are promising comple-
mentary tools to develop new safe- and useful-by-design 
compounds.
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Additional file 3. File containing the R functions and scripts to create the 
integrative model.
Additional file 4. Fig. S1. Estimation of the optimal λ; value with the RSVA 
algorithm.
Additional file 5. Fig. S2. Comparison of the model validation curves.
Additional file 6. Fig. S3. Scatterplot of experimental vs. predicted 
 logKHSA values of the 59 drugs, coloured by ATC codes level 1 and 2.
Additional file 7. Fig. S4. Boxplot of the predicted  logKHSA values of the 
799 external compounds coming from CMap dataset grouped by ATC 
codes level 1.
Additional file 8. Fig. S5. Boxplot of the predicted  logKHSA values of the 
799 external compounds coming from CMap dataset grouped by ATC 
codes level 2.
Additional file 9. Fig. S6. Boxplot of the expression values of the three 
selected genes, grouped by immunosuppressant and their less similar 
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